TMCnet News
Global Endometriosis Pipeline Review 2016: Focus on 23 Companies & 42 Molecules - Research and MarketsResearch and Markets has announced the addition of the "Endometriosis - Pipeline Review, H2 2016" report to their offering. Endometriosis pipeline therapeutics constitutes close to 42 molecules. Out of which approximately 34 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 7, 6, 11, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively. Endometriosis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. Key Topics Covered:
About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006408/en/ |
